[
  {
    "ts": null,
    "headline": "Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome",
    "summary": "– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunersen – CAMBRIDGE, Mass. and BEDFORD, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) a",
    "url": "https://finnhub.io/api/news?id=bbf464889fae0e8581c8eb9e8b855dfe854e7da62b1bab0617f7adbe28b5d546",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760041800,
      "headline": "Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome",
      "id": 137042316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunersen – CAMBRIDGE, Mass. and BEDFORD, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) a",
      "url": "https://finnhub.io/api/news?id=bbf464889fae0e8581c8eb9e8b855dfe854e7da62b1bab0617f7adbe28b5d546"
    }
  },
  {
    "ts": null,
    "headline": "Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome",
    "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., October 09, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of longer-term follow-up analyses from the ongoing open-label extension (OLE) studies of zorevunersen that support the potential of zorevunersen as a disease-modifying medicine for Dravet syndrome. These new results were",
    "url": "https://finnhub.io/api/news?id=2d30cd25ce7458abc10e41ae9288c9ed410bf26a3e05416c9127f839537edca9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760041800,
      "headline": "Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome",
      "id": 137042315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BEDFORD, Mass., & CAMBRIDGE, Mass., October 09, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced the presentation of longer-term follow-up analyses from the ongoing open-label extension (OLE) studies of zorevunersen that support the potential of zorevunersen as a disease-modifying medicine for Dravet syndrome. These new results were",
      "url": "https://finnhub.io/api/news?id=2d30cd25ce7458abc10e41ae9288c9ed410bf26a3e05416c9127f839537edca9"
    }
  },
  {
    "ts": null,
    "headline": "Biogen's Comeback: Why The Bulls Are Finally Winning Again",
    "summary": "Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!",
    "url": "https://finnhub.io/api/news?id=383280829b2d65aaee260fb6f2f591ba8b014cf9ddb2d4176528405b0c43ff9d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760007294,
      "headline": "Biogen's Comeback: Why The Bulls Are Finally Winning Again",
      "id": 137032305,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2187871109/image_2187871109.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "Discover why Biogen's MS drug growth, robust margins, and Alcyone acquisition signal a 'Strong Buy.' Get expert stock insightsâread the full analysis now!",
      "url": "https://finnhub.io/api/news?id=383280829b2d65aaee260fb6f2f591ba8b014cf9ddb2d4176528405b0c43ff9d"
    }
  },
  {
    "ts": null,
    "headline": "1 Value Stock with Promising Prospects and 2 We Avoid",
    "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
    "url": "https://finnhub.io/api/news?id=220f3359cecd45841283845c8acc848253b64d92843a22648455f926c536894c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759984993,
      "headline": "1 Value Stock with Promising Prospects and 2 We Avoid",
      "id": 137028558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.",
      "url": "https://finnhub.io/api/news?id=220f3359cecd45841283845c8acc848253b64d92843a22648455f926c536894c"
    }
  }
]